pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
ROCHE · news · pharmadog
← back to ROCHE
News mentioning ROCHE
260
stories
8d
Roche cans muscle-preserving obesity drug, hands it back to Chugai
endpoints
8d
Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitor
biospace
8d
STAT+: Pharmalittle: We’re reading about GLP-1s becoming lifestyle drugs, a setback for Merck and Daiichi, and more
stat
8d
Merck, Daiichi end plans to seek speedy approval of lung cancer ADC
biopharma dive
8d
Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC
biospace
8d
Roche drops muscle-sparing obesity antibody after flunked interim analysis
fiercebiotech
10d
STAT+: Licensing deals on generic versions of Roche flu drug aimed at preparing for pandemic
stat
11d
STAT+: Pharmalittle: We’re reading about a reticent FDA commish nominee, a Novo deal, and more
stat
11d
Genentech makes $1.5B+ deal with AI heavyweight Earendil for cancer bispecifics
biospace
11d
Travere CEO Eric Dube on deciding to leave; Roche tees up a board seat for ex-Takeda chief
endpoints
11d
Roche's Genentech inks $1.5B bispecific pact with fast-rising Earendil
fiercebiotech
11d
Merck reveals study success, and possible safety worries, for eye drug hopeful
biopharma dive
11d
Roche secures separate discovery deals with Atavistik, Earendil
endpoints
11d
Chutes & Ladders—Travere chief makes way for former Amicus CEO
fiercebiotech
12d
STAT+: Indonesian ruling against ‘patent evergreening’ by pharma industry sends critical message, patient advocates say
stat
12d
Lilly’s latest China drug deal; Immunovant’s setback in lupus
biopharma dive
12d
Merck’s experimental eye drug matches Roche’s VEGF inhibitor but safety concerns emerge
biospace
12d
Backed by NVIDIA, Basecamp bags $140M to advance AI-designed drugs
biospace
12d
Backed by NVIDIA and Anthropic, Basecamp bags $140M to advance AI-designed drugs
biospace
12d
Roche inks up to $2B deal with Atavistik for new cardiometabolic drugs
biospace
12d
China’s Henlius carves out $440M T-cell engager deal with Amberstone
fiercebiotech
12d
Merck sees pivotal victory for $3B eye disease prospect
fiercebiotech
12d
Roche pens backloaded $2B deal with Atavistik to discover allosteric CVRM drugs
fiercebiotech
12d
Roche, Ionis RNA drug scores in kidney disease study
biopharma dive
12d
9 pharma leaders sound ‘alarm bells’ on biotech’s decline in Europe
biopharma dive
13d
Roche-Ionis’ RNA therapy reduces kidney disease marker, opening path to swift FDA nod
biospace
13d
STAT+: Pharmalittle: We’re reading about a closing loophole for importing meds, European competitiveness, and more
stat
13d
Ionis-Otsuka offer 'groundbreaking' improvement in function and survival for genetic type of ALS
biospace
13d
Roche kidney drug's Phase 3 win sets up path to accelerated approval
endpoints
13d
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz
biospace
← prev
page 2 of 9
next →
